$REGN Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in REGENERON PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in REGENERON PHARMACEUTICALS, INC.. Get notifications about new insider transactions in REGENERON PHARMACEUTICALS, INC. for free.
Page: < prev 1 2 3 4 5 6 7 ... 48 next >
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jul 15 2020 | REGN | REGENERON PHARMACE ... | MURPHY ANDREW J | EVP Research | Sell | S | 614.62 | 178 | 109,402 | 48,082 | 48.3 K to 48.1 K (-0.37 %) |
Jul 15 2020 | REGN | REGENERON PHARMACE ... | MURPHY ANDREW J | EVP Research | Payment of Exercise | F | 623.98 | 6,691 | 4,175,050 | 48,260 | 55 K to 48.3 K (-12.18 %) |
Jul 15 2020 | REGN | REGENERON PHARMACE ... | MURPHY ANDREW J | EVP Research | Buy | M | 30.63 | 13,000 | 398,190 | 54,951 | 42 K to 55 K (+30.99 %) |
Jul 15 2020 | REGN | REGENERON PHARMACE ... | MURPHY ANDREW J | EVP Research | Sell | S | 633.28 | 441 | 279,276 | 41,951 | 42.4 K to 42 K (-1.04 %) |
Jul 15 2020 | REGN | REGENERON PHARMACE ... | MURPHY ANDREW J | EVP Research | Sell | S | 632.65 | 680 | 430,202 | 42,392 | 43.1 K to 42.4 K (-1.58 %) |
Jul 15 2020 | REGN | REGENERON PHARMACE ... | MURPHY ANDREW J | EVP Research | Sell | S | 631.45 | 861 | 543,678 | 43,072 | 43.9 K to 43.1 K (-1.96 %) |
Jul 15 2020 | REGN | REGENERON PHARMACE ... | MURPHY ANDREW J | EVP Research | Sell | S | 630.50 | 1,423 | 897,202 | 43,933 | 45.4 K to 43.9 K (-3.14 %) |
Jul 15 2020 | REGN | REGENERON PHARMACE ... | MURPHY ANDREW J | EVP Research | Sell | S | 629.62 | 883 | 555,954 | 45,356 | 46.2 K to 45.4 K (-1.91 %) |
Jul 15 2020 | REGN | REGENERON PHARMACE ... | MURPHY ANDREW J | EVP Research | Sell | S | 628.32 | 259 | 162,735 | 46,239 | 46.5 K to 46.2 K (-0.56 %) |
Jul 15 2020 | REGN | REGENERON PHARMACE ... | MURPHY ANDREW J | EVP Research | Sell | S | 627.54 | 657 | 412,294 | 46,498 | 47.2 K to 46.5 K (-1.39 %) |
Jul 15 2020 | REGN | REGENERON PHARMACE ... | MURPHY ANDREW J | EVP Research | Sell | S | 626.63 | 1,003 | 628,510 | 47,155 | 48.2 K to 47.2 K (-2.08 %) |
Jul 15 2020 | REGN | REGENERON PHARMACE ... | MURPHY ANDREW J | EVP Research | Sell | S | 625.86 | 173 | 108,274 | 48,158 | 48.3 K to 48.2 K (-0.36 %) |
Jul 15 2020 | REGN | REGENERON PHARMACE ... | MURPHY ANDREW J | EVP Research | Sell | S | 624.47 | 370 | 231,054 | 48,331 | 48.7 K to 48.3 K (-0.76 %) |
Jul 15 2020 | REGN | REGENERON PHARMACE ... | MURPHY ANDREW J | EVP Research | Sell | S | 623.66 | 740 | 461,508 | 48,701 | 49.4 K to 48.7 K (-1.50 %) |
Jul 15 2020 | REGN | REGENERON PHARMACE ... | MURPHY ANDREW J | EVP Research | Sell | S | 622.74 | 333 | 207,372 | 49,441 | 49.8 K to 49.4 K (-0.67 %) |
Jul 15 2020 | REGN | REGENERON PHARMACE ... | MURPHY ANDREW J | EVP Research | Sell | S | 621.98 | 81 | 50,380 | 49,774 | 49.9 K to 49.8 K (-0.16 %) |
Jul 15 2020 | REGN | REGENERON PHARMACE ... | MURPHY ANDREW J | EVP Research | Sell | S | 620.64 | 96 | 59,581 | 49,855 | 50 K to 49.9 K (-0.19 %) |
Jul 14 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 640.50 | 579 | 370,850 | 23,973 | 24.6 K to 24 K (-2.36 %) |
Jul 13 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 399.66 | 3,000 | 1,198,980 | 28,500 | |
Jul 13 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 642.46 | 2,421 | 1,555,396 | 24,552 | 27 K to 24.6 K (-8.98 %) |
Jul 13 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 399.66 | 3,000 | 1,198,980 | 26,973 | 24 K to 27 K (+12.51 %) |
Jul 09 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 555.67 | 10,000 | 5,556,700 | 10,000 | |
Jul 09 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 399.66 | 2,500 | 999,150 | 31,500 | |
Jul 09 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 650.41 | 3 | 1,951 | 23,973 | 24 K to 24 K (-0.01 %) |
Jul 09 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 648.54 | 94 | 60,963 | 23,976 | 24.1 K to 24 K (-0.39 %) |
Jul 09 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 646.18 | 37 | 23,909 | 24,070 | 24.1 K to 24.1 K (-0.15 %) |
Jul 09 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 645.99 | 57 | 36,821 | 24,107 | 24.2 K to 24.1 K (-0.24 %) |
Jul 09 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 643.84 | 104 | 66,959 | 24,164 | 24.3 K to 24.2 K (-0.43 %) |
Jul 09 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 642.93 | 48 | 30,861 | 24,268 | 24.3 K to 24.3 K (-0.20 %) |
Jul 09 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 640.32 | 43 | 27,534 | 24,316 | 24.4 K to 24.3 K (-0.18 %) |
Jul 09 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 639.88 | 80 | 51,190 | 24,359 | 24.4 K to 24.4 K (-0.33 %) |
Jul 09 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 638.99 | 45 | 28,755 | 24,439 | 24.5 K to 24.4 K (-0.18 %) |
Jul 09 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 637.40 | 40 | 25,496 | 24,484 | 24.5 K to 24.5 K (-0.16 %) |
Jul 09 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 636.50 | 585 | 372,353 | 24,524 | 25.1 K to 24.5 K (-2.33 %) |
Jul 09 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 634.14 | 24 | 15,219 | 25,109 | 25.1 K to 25.1 K (-0.10 %) |
Jul 09 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 640.88 | 2,019 | 1,293,937 | 25,133 | 27.2 K to 25.1 K (-7.44 %) |
Jul 09 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 399.66 | 2,500 | 999,150 | 27,152 | 24.7 K to 27.2 K (+10.14 %) |
Jul 09 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 640.88 | 9,321 | 5,973,642 | 24,652 | 34 K to 24.7 K (-27.44 %) |
Jul 09 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 555.67 | 10,000 | 5,556,700 | 33,973 | 24 K to 34 K (+41.71 %) |
Jul 08 2020 | REGN | REGENERON PHARMACE ... | SING GEORGE L | Director | Option Exercise | M | 33.42 | 7,500 | 250,650 | 0 | |
Jul 08 2020 | REGN | REGENERON PHARMACE ... | SING GEORGE L | Director | Sell | S | 650.00 | 1,500 | 975,000 | 4,700 | 6.2 K to 4.7 K (-24.19 %) |
Jul 08 2020 | REGN | REGENERON PHARMACE ... | SING GEORGE L | Director | Sell | S | 651.09 | 200 | 130,218 | 400 | 600 to 400 (-33.33 %) |
Jul 08 2020 | REGN | REGENERON PHARMACE ... | SING GEORGE L | Director | Sell | S | 650.32 | 800 | 520,256 | 600 | 1.4 K to 600 (-57.14 %) |
Jul 08 2020 | REGN | REGENERON PHARMACE ... | SING GEORGE L | Director | Sell | S | 650.00 | 500 | 325,000 | 1,150 | 1.7 K to 1.2 K (-30.30 %) |
Jul 08 2020 | REGN | REGENERON PHARMACE ... | SING GEORGE L | Director | Sell | S | 650.00 | 7,500 | 4,875,000 | 115,415 | 122.9 K to 115.4 K (-6.10 %) |
Jul 08 2020 | REGN | REGENERON PHARMACE ... | SING GEORGE L | Director | Buy | M | 33.42 | 7,500 | 250,650 | 122,915 | 115.4 K to 122.9 K (+6.50 %) |
Jul 08 2020 | REGN | REGENERON PHARMACE ... | Zoghbi Huda Y | Director | Option Exercise | M | 391.92 | 1,706 | 668,616 | 5,117 | |
Jul 08 2020 | REGN | REGENERON PHARMACE ... | Zoghbi Huda Y | Director | Sell | S | 650.00 | 1,706 | 1,108,900 | 643 | 2.3 K to 643 (-72.63 %) |
Jul 08 2020 | REGN | REGENERON PHARMACE ... | Zoghbi Huda Y | Director | Buy | M | 391.92 | 1,706 | 668,616 | 2,349 | 643 to 2.3 K (+265.32 %) |
Jul 02 2020 | REGN | REGENERON PHARMACE ... | BROWN MICHAEL S | Director | Option Exercise | M | 413.33 | 3,613 | 1,493,361 | 7,225 | |
Jul 02 2020 | REGN | REGENERON PHARMACE ... | BROWN MICHAEL S | Director | Sell | S | 612.29 | 400 | 244,916 | 643 | 1 K to 643 (-38.35 %) |
Jul 02 2020 | REGN | REGENERON PHARMACE ... | BROWN MICHAEL S | Director | Sell | S | 607.35 | 200 | 121,470 | 1,043 | 1.2 K to 1 K (-16.09 %) |
Jul 02 2020 | REGN | REGENERON PHARMACE ... | BROWN MICHAEL S | Director | Sell | S | 624.19 | 6 | 3,745 | 1,243 | 1.2 K to 1.2 K (-0.48 %) |
Jul 02 2020 | REGN | REGENERON PHARMACE ... | BROWN MICHAEL S | Director | Sell | S | 623.07 | 100 | 62,307 | 1,249 | 1.3 K to 1.2 K (-7.41 %) |
Jul 02 2020 | REGN | REGENERON PHARMACE ... | BROWN MICHAEL S | Director | Sell | S | 616.49 | 200 | 123,298 | 1,349 | 1.5 K to 1.3 K (-12.91 %) |
Jul 02 2020 | REGN | REGENERON PHARMACE ... | BROWN MICHAEL S | Director | Sell | S | 615.23 | 100 | 61,523 | 1,549 | 1.6 K to 1.5 K (-6.06 %) |
Jul 02 2020 | REGN | REGENERON PHARMACE ... | BROWN MICHAEL S | Director | Sell | S | 609.51 | 200 | 121,902 | 1,649 | 1.8 K to 1.6 K (-10.82 %) |
Jul 02 2020 | REGN | REGENERON PHARMACE ... | BROWN MICHAEL S | Director | Sell | S | 608.59 | 319 | 194,140 | 1,849 | 2.2 K to 1.8 K (-14.71 %) |
Jul 02 2020 | REGN | REGENERON PHARMACE ... | BROWN MICHAEL S | Director | Sell | S | 605.78 | 401 | 242,918 | 2,168 | 2.6 K to 2.2 K (-15.61 %) |
Jul 02 2020 | REGN | REGENERON PHARMACE ... | BROWN MICHAEL S | Director | Sell | S | 604.82 | 960 | 580,627 | 2,569 | 3.5 K to 2.6 K (-27.20 %) |
Jul 02 2020 | REGN | REGENERON PHARMACE ... | BROWN MICHAEL S | Director | Sell | S | 603.39 | 627 | 378,326 | 3,529 | 4.2 K to 3.5 K (-15.09 %) |
Jul 02 2020 | REGN | REGENERON PHARMACE ... | BROWN MICHAEL S | Director | Sell | S | 601.70 | 100 | 60,170 | 4,156 | 4.3 K to 4.2 K (-2.35 %) |
Jul 02 2020 | REGN | REGENERON PHARMACE ... | BROWN MICHAEL S | Director | Buy | M | 413.33 | 3,613 | 1,493,361 | 4,256 | 643 to 4.3 K (+561.90 %) |
Jun 30 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 616.67 | 31 | 19,117 | 23,973 | 24 K to 24 K (-0.13 %) |
Jun 30 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 614.64 | 69 | 42,410 | 24,004 | 24.1 K to 24 K (-0.29 %) |
Jun 30 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 612.67 | 153 | 93,739 | 24,073 | 24.2 K to 24.1 K (-0.63 %) |
Jun 30 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 611.44 | 50 | 30,572 | 24,226 | 24.3 K to 24.2 K (-0.21 %) |
Jun 30 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 610.73 | 58 | 35,422 | 24,276 | 24.3 K to 24.3 K (-0.24 %) |
Jun 30 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 609.46 | 39 | 23,769 | 24,334 | 24.4 K to 24.3 K (-0.16 %) |
Jun 29 2020 | REGN | REGENERON PHARMACE ... | SING GEORGE L | Director | Sell | S | 609.37 | 1,500 | 914,055 | 6,200 | 7.7 K to 6.2 K (-19.48 %) |
Jun 29 2020 | REGN | REGENERON PHARMACE ... | SING GEORGE L | Director | Sell | S | 609.68 | 100 | 60,968 | 1,400 | 1.5 K to 1.4 K (-6.67 %) |
Jun 29 2020 | REGN | REGENERON PHARMACE ... | SING GEORGE L | Director | Sell | S | 608.29 | 500 | 304,145 | 1,500 | 2 K to 1.5 K (-25.00 %) |
Jun 29 2020 | REGN | REGENERON PHARMACE ... | SING GEORGE L | Director | Sell | S | 607.54 | 200 | 121,508 | 2,000 | 2.2 K to 2 K (-9.09 %) |
Jun 29 2020 | REGN | REGENERON PHARMACE ... | SING GEORGE L | Director | Sell | S | 606.80 | 200 | 121,360 | 2,200 | 2.4 K to 2.2 K (-8.33 %) |
Jun 29 2020 | REGN | REGENERON PHARMACE ... | SING GEORGE L | Director | Sell | S | 609.37 | 500 | 304,685 | 1,650 | 2.2 K to 1.7 K (-23.26 %) |
Jun 24 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 555.67 | 8,900 | 4,945,463 | 20,000 | |
Jun 24 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 635.24 | 46 | 29,221 | 24,373 | 24.4 K to 24.4 K (-0.19 %) |
Jun 24 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 634.63 | 89 | 56,482 | 24,419 | 24.5 K to 24.4 K (-0.36 %) |
Jun 24 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 633.56 | 82 | 51,952 | 24,508 | 24.6 K to 24.5 K (-0.33 %) |
Jun 24 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 631.25 | 78 | 49,238 | 24,590 | 24.7 K to 24.6 K (-0.32 %) |
Jun 24 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 630.84 | 82 | 51,729 | 24,668 | 24.8 K to 24.7 K (-0.33 %) |
Jun 24 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 628.64 | 39 | 24,517 | 24,750 | 24.8 K to 24.8 K (-0.16 %) |
Jun 24 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 626.56 | 56 | 35,087 | 24,789 | 24.8 K to 24.8 K (-0.23 %) |
Jun 24 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 624.65 | 40 | 24,986 | 24,845 | 24.9 K to 24.8 K (-0.16 %) |
Jun 24 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 626.19 | 8,388 | 5,252,482 | 24,885 | 33.3 K to 24.9 K (-25.21 %) |
Jun 24 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 555.67 | 8,900 | 4,945,463 | 33,273 | 24.4 K to 33.3 K (+36.52 %) |
Jun 22 2020 | REGN | REGENERON PHARMACE ... | Bassler Bonnie L | Director | Option Exercise | M | 391.92 | 2,559 | 1,002,923 | 10,235 | |
Jun 22 2020 | REGN | REGENERON PHARMACE ... | Bassler Bonnie L | Director | Sell | S | 631.37 | 11 | 6,945 | 643 | 654 to 643 (-1.68 %) |
Jun 22 2020 | REGN | REGENERON PHARMACE ... | Bassler Bonnie L | Director | Sell | S | 630.01 | 2,548 | 1,605,265 | 654 | 3.2 K to 654 (-79.58 %) |
Jun 22 2020 | REGN | REGENERON PHARMACE ... | Bassler Bonnie L | Director | Buy | M | 391.92 | 2,559 | 1,002,923 | 3,202 | 643 to 3.2 K (+397.98 %) |
Jun 17 2020 | REGN | REGENERON PHARMACE ... | Fenimore Christopher R. | VP Controller | Option Exercise | M | 52.03 | 7,226 | 375,969 | 0 | |
Jun 17 2020 | REGN | REGENERON PHARMACE ... | Fenimore Christopher R. | VP Controller | Option Exercise | M | 30.63 | 2,180 | 66,773 | 0 | |
Jun 17 2020 | REGN | REGENERON PHARMACE ... | Fenimore Christopher R. | VP Controller | Sell | S | 596.36 | 294 | 175,330 | 15,277 | 15.6 K to 15.3 K (-1.89 %) |
Jun 17 2020 | REGN | REGENERON PHARMACE ... | Fenimore Christopher R. | VP Controller | Sell | S | 595.50 | 403 | 239,987 | 15,571 | 16 K to 15.6 K (-2.52 %) |
Jun 17 2020 | REGN | REGENERON PHARMACE ... | Fenimore Christopher R. | VP Controller | Sell | S | 594.35 | 747 | 443,979 | 15,974 | 16.7 K to 16 K (-4.47 %) |
Jun 17 2020 | REGN | REGENERON PHARMACE ... | Fenimore Christopher R. | VP Controller | Sell | S | 593.25 | 109 | 64,664 | 16,721 | 16.8 K to 16.7 K (-0.65 %) |
Jun 17 2020 | REGN | REGENERON PHARMACE ... | Fenimore Christopher R. | VP Controller | Sell | S | 592.20 | 214 | 126,731 | 16,830 | 17 K to 16.8 K (-1.26 %) |
Jun 17 2020 | REGN | REGENERON PHARMACE ... | Fenimore Christopher R. | VP Controller | Sell | S | 591.61 | 233 | 137,845 | 17,044 | 17.3 K to 17 K (-1.35 %) |
Jun 17 2020 | REGN | REGENERON PHARMACE ... | Fenimore Christopher R. | VP Controller | Sell | S | 590.70 | 153 | 90,377 | 17,277 | 17.4 K to 17.3 K (-0.88 %) |
Jun 17 2020 | REGN | REGENERON PHARMACE ... | Fenimore Christopher R. | VP Controller | Sell | S | 588.80 | 147 | 86,554 | 17,430 | 17.6 K to 17.4 K (-0.84 %) |
Jun 17 2020 | REGN | REGENERON PHARMACE ... | Fenimore Christopher R. | VP Controller | Sell | S | 587.55 | 373 | 219,156 | 17,577 | 18 K to 17.6 K (-2.08 %) |
Jun 17 2020 | REGN | REGENERON PHARMACE ... | Fenimore Christopher R. | VP Controller | Sell | S | 586.54 | 413 | 242,241 | 17,950 | 18.4 K to 18 K (-2.25 %) |
Jun 17 2020 | REGN | REGENERON PHARMACE ... | Fenimore Christopher R. | VP Controller | Sell | S | 585.76 | 130 | 76,149 | 18,363 | 18.5 K to 18.4 K (-0.70 %) |
Jun 17 2020 | REGN | REGENERON PHARMACE ... | Fenimore Christopher R. | VP Controller | Sell | S | 584.62 | 99 | 57,877 | 18,493 | 18.6 K to 18.5 K (-0.53 %) |
Jun 17 2020 | REGN | REGENERON PHARMACE ... | Fenimore Christopher R. | VP Controller | Sell | S | 583.06 | 111 | 64,720 | 18,592 | 18.7 K to 18.6 K (-0.59 %) |
Jun 17 2020 | REGN | REGENERON PHARMACE ... | Fenimore Christopher R. | VP Controller | Sell | S | 582.69 | 18 | 10,488 | 18,703 | 18.7 K to 18.7 K (-0.10 %) |
Jun 17 2020 | REGN | REGENERON PHARMACE ... | Fenimore Christopher R. | VP Controller | Sell | S | 581.40 | 112 | 65,117 | 18,721 | 18.8 K to 18.7 K (-0.59 %) |
Jun 17 2020 | REGN | REGENERON PHARMACE ... | Fenimore Christopher R. | VP Controller | Buy | M | 30.63 | 2,180 | 66,773 | 18,833 | 16.7 K to 18.8 K (+13.09 %) |
Jun 17 2020 | REGN | REGENERON PHARMACE ... | Fenimore Christopher R. | VP Controller | Payment of Exercise | F | 587.90 | 3,670 | 2,157,593 | 16,653 | 20.3 K to 16.7 K (-18.06 %) |
Jun 17 2020 | REGN | REGENERON PHARMACE ... | Fenimore Christopher R. | VP Controller | Buy | M | 52.03 | 7,226 | 375,969 | 20,323 | 13.1 K to 20.3 K (+55.17 %) |
Jun 12 2020 | REGN | REGENERON PHARMACE ... | Zoghbi Huda Y | Director | Option Exercise | M | 391.92 | 1,706 | 668,616 | 6,823 | |
Jun 12 2020 | REGN | REGENERON PHARMACE ... | Zoghbi Huda Y | Director | Option Exercise | M | 391.92 | 1,706 | 668,616 | 8,529 | |
Jun 12 2020 | REGN | REGENERON PHARMACE ... | Zoghbi Huda Y | Director | Sell | S | 625.00 | 1,706 | 1,066,250 | 643 | 2.3 K to 643 (-72.63 %) |
Jun 12 2020 | REGN | REGENERON PHARMACE ... | Zoghbi Huda Y | Director | Buy | M | 391.92 | 1,706 | 668,616 | 2,349 | 643 to 2.3 K (+265.32 %) |
Jun 12 2020 | REGN | REGENERON PHARMACE ... | Zoghbi Huda Y | Director | Sell | S | 616.19 | 99 | 61,003 | 643 | 742 to 643 (-13.34 %) |
Jun 12 2020 | REGN | REGENERON PHARMACE ... | Zoghbi Huda Y | Director | Sell | S | 615.28 | 80 | 49,222 | 742 | 822 to 742 (-9.73 %) |
Jun 12 2020 | REGN | REGENERON PHARMACE ... | Zoghbi Huda Y | Director | Sell | S | 613.03 | 5 | 3,065 | 822 | 827 to 822 (-0.60 %) |
Jun 12 2020 | REGN | REGENERON PHARMACE ... | Zoghbi Huda Y | Director | Sell | S | 612.52 | 265 | 162,318 | 827 | 1.1 K to 827 (-24.27 %) |
Jun 12 2020 | REGN | REGENERON PHARMACE ... | Zoghbi Huda Y | Director | Sell | S | 611.46 | 164 | 100,279 | 1,092 | 1.3 K to 1.1 K (-13.06 %) |
Jun 12 2020 | REGN | REGENERON PHARMACE ... | Zoghbi Huda Y | Director | Sell | S | 610.41 | 202 | 123,303 | 1,256 | 1.5 K to 1.3 K (-13.85 %) |
Jun 12 2020 | REGN | REGENERON PHARMACE ... | Zoghbi Huda Y | Director | Sell | S | 609.48 | 161 | 98,126 | 1,458 | 1.6 K to 1.5 K (-9.94 %) |
Jun 12 2020 | REGN | REGENERON PHARMACE ... | Zoghbi Huda Y | Director | Sell | S | 608.62 | 330 | 200,845 | 1,619 | 1.9 K to 1.6 K (-16.93 %) |
Jun 12 2020 | REGN | REGENERON PHARMACE ... | Zoghbi Huda Y | Director | Sell | S | 607.64 | 251 | 152,518 | 1,949 | 2.2 K to 1.9 K (-11.41 %) |
Jun 12 2020 | REGN | REGENERON PHARMACE ... | Zoghbi Huda Y | Director | Sell | S | 606.64 | 149 | 90,389 | 2,200 | 2.3 K to 2.2 K (-6.34 %) |
Jun 12 2020 | REGN | REGENERON PHARMACE ... | Zoghbi Huda Y | Director | Buy | M | 391.92 | 1,706 | 668,616 | 2,349 | 643 to 2.3 K (+265.32 %) |
Jun 12 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 3,500 | 954,450 | 0 | |
Jun 12 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 624.56 | 59 | 36,849 | 24,373 | 24.4 K to 24.4 K (-0.24 %) |
Jun 12 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 621.56 | 16 | 9,945 | 24,432 | 24.4 K to 24.4 K (-0.07 %) |
Jun 12 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 620.70 | 58 | 36,001 | 24,448 | 24.5 K to 24.4 K (-0.24 %) |
Jun 12 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 619.73 | 66 | 40,902 | 24,506 | 24.6 K to 24.5 K (-0.27 %) |
Jun 12 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 616.00 | 31 | 19,096 | 24,572 | 24.6 K to 24.6 K (-0.13 %) |
Jun 12 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 614.41 | 34 | 20,890 | 24,603 | 24.6 K to 24.6 K (-0.14 %) |
Jun 12 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 613.53 | 23 | 14,111 | 24,637 | 24.7 K to 24.6 K (-0.09 %) |
Jun 12 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 612.74 | 177 | 108,455 | 24,660 | 24.8 K to 24.7 K (-0.71 %) |
Jun 12 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 611.82 | 14 | 8,565 | 24,837 | 24.9 K to 24.8 K (-0.06 %) |
Jun 12 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 608.91 | 65 | 39,579 | 24,851 | 24.9 K to 24.9 K (-0.26 %) |
Jun 12 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 607.50 | 445 | 270,338 | 24,916 | 25.4 K to 24.9 K (-1.75 %) |
Jun 12 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 610.18 | 2,512 | 1,532,772 | 25,361 | 27.9 K to 25.4 K (-9.01 %) |
Jun 12 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 3,500 | 954,450 | 27,873 | 24.4 K to 27.9 K (+14.36 %) |
Jun 11 2020 | REGN | REGENERON PHARMACE ... | Sanofi | Sell | S | 597.48 | 120,234 | 71,837,410 | 279,766 | 400 K to 279.8 K (-30.06 %) | |
Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 1,500 | 409,050 | 3,500 | |
Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 2,250 | 613,575 | 5,000 | |
Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 2,250 | 613,575 | 7,250 | |
Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 2,500 | 681,750 | 9,500 | |
Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 3,500 | 954,450 | 12,000 | |
Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 3,500 | 954,450 | 15,500 | |
Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 610.25 | 527 | 321,602 | 24,373 | 24.9 K to 24.4 K (-2.12 %) |
Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 609.53 | 681 | 415,090 | 24,900 | 25.6 K to 24.9 K (-2.66 %) |
Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 608.50 | 1,511 | 919,444 | 25,581 | 27.1 K to 25.6 K (-5.58 %) |
Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 607.47 | 619 | 376,024 | 27,092 | 27.7 K to 27.1 K (-2.23 %) |